Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5305526 | 0.76 | HTR7 (0.37) | ALDH1A1 | |
| SCHEMBL3018505 | 0.74 | ALDH1A1 (0.35) | KDM4EMEN1ALDH1A1THRBKMT2A | |
| SCHEMBL27432364 | 0.71 | OPRM1 (0.34) | — | |
| SCHEMBL1639188 | 0.71 | MAPT (0.43) | — | |
| SCHEMBL9786119 | 0.71 | MAPT (0.43) | — | |
| SCHEMBL9786152 | 0.69 | ALDH1A1 (0.37) | KDM4EMEN1ALDH1A1KMT2A | |
| SCHEMBL5802520 | 0.69 | ALDH1A1 (0.37) | KDM4EMEN1ALDH1A1KMT2A | |
| Hydrochloric Acid SCHEMBL27459404 | 0.69 | HTR2C (0.36) | — | |
| SCHEMBL28216170 | 0.69 | HTR2B (0.34) | — | |
| SCHEMBL12900540 | 0.68 | ROCK2 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722681-B2 | N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases | NV REMYND (BE) | 2014-05-13 | — | — | US | claimed |
| US-5210193-A | Bactericide | AMERICAN CYANAMID COMPANY (US) | 1993-05-11 | — | — | US | claimed |
| US-8722681-B2 | N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases | NV REMYND (BE) | 2014-05-13 | — | — | US | disclosed |
| US-20100197703-A1 | N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | NV REMYND (BE) | 2010-08-05 | — | — | US | disclosed |
| US-5210193-A | Bactericide | AMERICAN CYANAMID COMPANY (US) | 1993-05-11 | — | — | US | disclosed |
| US-4940710-A | 7-(substituted)piperazinyl-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids | AMERICAN CYANAMID COMPANY (US) | 1990-07-10 | — | — | US | disclosed |
| EP-0230053-A2 | 7-(Substituted)piperazinyl-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids | AMERICAN CYANAMID COMPANY (US) | 1987-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197703-A1 | N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | SMN1; SMN2, HTT, SNCA | KDM4E 4398/4885MEN1 454/4885ALDH1A1 3510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.